Clinical/therapeutic approaches for cannabinoid ligands in central and peripheral nervous system diseases: Mini review

Clinical Neuropharmacology

Volumn 39, Issue 2, 2016, Pages 94-101

  Fijal, Katarzyna ^a,b   Filip, Magorzata ^a,b  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Cannabinoids; Clinical trials; Neurological disorders; Psychiatric diseases

Indexed keywords

ANALGESIC AGENT; BACLOFEN; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR AFFECTING AGENT; DRONABINOL; HALOPERIDOL; NABILONE; NABIXIMOLS; OPIATE; PLACEBO; RIMONABANT; LIGAND;

ANALGESIA; ANALGESIC ACTIVITY; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE DEFECT; COMPLEX REGIONAL PAIN SYNDROME; COMPULSION; DIABETIC NEUROPATHY; DRUG EFFICACY; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; HIV ASSOCIATED NEPHROPATHY; HUMAN; MEDICAL LITERATURE; MEDLINE; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; NONHUMAN; PAIN THRESHOLD; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SENSORY NEUROPATHY; SOCIAL PHOBIA; SPASTICITY; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; TRICHOTILLOMANIA; NERVOUS SYSTEM DISEASES; PERIPHERAL NERVOUS SYSTEM DISEASES;

CANNABINOIDS; HUMANS; LIGANDS; NERVOUS SYSTEM DISEASES; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84955587229     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0000000000000132     Document Type: Review

References (50)

1. Basavarajappa BS. Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity. Curr Neuropharmacol 2007;5(2):81-97.
2. Mechoulam R, Linda A, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol 2013;64:6.1-6.27.
3. Pazos MR, Núñez E, Benito C, et al. Functional neuroanatomy of the endocannabinoid system. Pharmacol Biochem Behav 2005;81(2): 239-247.
4. Davis MP. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands. Expert Opin Investig Drugs 2014;23(8):1123-1140.
5. Farrimond JA, Mercier MS, Whalley BJ, et al. Cannabis sativa and the endogenous cannabinoid system: therapeutic potential for appetite regulation. Phytother Res 2011;25(2):170-188.
6. Hosking RD, Zajicek JP. Therapeutic potential of cannabis in pain medicine. Br J Anaesth 2008;101(1):59-68.
7. Lorente Fernández L, Monte Boquet E, Pérez-Miralles F, et al. Clinical experiences with cannabinoids in spasticity management in multiple sclerosis. Neurologia 2014;29:257-260.
8. Malik Z, Baik D, Schey R. The role of cannabinoids in regulation of nausea and vomiting, and visceral pain. Curr Gastroenterol Rep 2015;17(2):429.
9. Pacher P. Towards the use of non-psychoactive cannabinoids for prostate cancer. Br J Pharmacol 2013;168(1):76-78.
10. Rom S, Persidsky Y. Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation. J Neuroimmune Pharmacol 2013;8(3):608-620.
11. Romano B, Borrelli F, Pagano E, et al. Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol. Phytomedicine 2014;21(5):631-639.
12. Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009;156(3):397-411.
13. Pertwee RG. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci 2012;367(1607): 3353-3363.
14. Todaro B. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. J Natl Compr Canc Netw 2012;10(4): 487-492.
15. Niesink RJ, van Laar MW. Does cannabidiol protect against adverse psychological effects of THC? Front Psychiatry 2013;4:130.
16. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007;68:515-521.
17. Wilsey B, Marcotte T, Tsodikov A, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain 2008;9: 506-521.
18. Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2009;34:672-680.
19. Portenoy RK, Ganae-Motan ED, Allende S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 2012;13: 438-449.
20. Johnson JR, Burnell-Nugent M, Lossignol D, et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 2010;39(2):167-179.
21. Johnson JR, Lossignol D, Burnell-Nugent M, et al. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage 2013;46(2):207-218.
22. Blake DR, Robson P, Ho M, et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 2006;45(1):50-52.
23. Serpell MG, Notcutt W, Collin C. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol 2013;260(1):285-295.
24. Selvarajah D, Gandhi R, Emery CJ, et al. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care 2010;33(1):128-130.
25. Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65(6):812-819.
26. Conte A, Bettolo CM, Onesti E, et al. Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis. Eur J Pain 2009;13(5): 472-477.
27. Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols∗ (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011;18:1122-1131.
28. Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo controlled study on 160 patients. Mult Scler 2004;10(4):434-441.
29. Collin C, Davies P, Mutiboko IK, et al. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007;14(3):290-296.
30. Notcutt W, Langford R, Davies P, et al. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex (nabiximols). Mult Scler 2012;18:219-228.
31. Flachenecker P, Henze T, Zettl UK. Nabiximols (THC/CBD oromucosal spray, Sativex) in clinical practice-results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol 2014;71(5-6):271-279.
32. Boggs DL, Kelly DL, McMahon RP, et al. Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial. Schizophr Res 2012;134(2-3):207-210.
33. Kelly DL, Gorelick DA, Conley RR, et al. Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol 2011;31(1):86-91.
34. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 2011;36: 1219-1226.
35. Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 2011;25(1):121-130.
36. Grant JE, Odlaug BL, Chamberlain SR, et al. Dronabinol, a cannabinoid agonist, reduces hair pulling in trichotillomania: a pilot study. Psychopharmacology (Berl) 2011;218(3):493-502.
37. Rahn EJ, Makriyannis A, Hohmann AG. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol 2007;152(5): 765-777.
38. Zhang L, Kline RH 4th, McNearney TA, et al. Cannabinoid receptor 2 agonist attenuates pain related behavior in rats with chronic alcohol/high fat diet induced pancreatitis. Mol Pain 2014;10:66.
39. Ueda M, Iwasaki H, Wang S, et al. Cannabinoid receptor type 1 antagonist, AM251, attenuates mechanical allodynia and thermal hyperalgesia after burn injury. Anesthesiology 2014;121: 1311-1319.
40. Wallace M, Schulteis G, Atkinson JH, et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 2007;107:785-796.
41. Cooper ZD, Comer SD, Haney M. Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers. Neuropsychopharmacology 2013;38:1984-1992.
42. Issa MA, Narang S, Jamison RN, et al. The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain. Clin J Pain 2014;30:472-478.
43. Maguire DR, Yang W, France CP. Interactions between μ-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination, and drug self-administration. J Pharmacol Exp Ther 2013;345(3):354-362.
44. Tham SM, Angus JA, Tudor EM, et al. Synergistic and additive interactions of the cannabinoid agonist CP55, 940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice. Br J Pharmacol 2005;144(166):875-884.
45. Bushlin I, Rozenfeld R, Devi LA. Cannabinoid-opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol 2010;10(1):80-86.
46. Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 2004;74:1317-1324.
47. Zuardi AW, Rodrigues JA, Cunha JM. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl) 1991;104:260-264.
48. Iseger TA, Bossong MG. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res 2015;162:153-161.
49. Cheung BM, Cheung TT, Samaranayake NR. Safety of antiobesity drugs. Ther Adv Drug Saf 2013;4(4):171-181.
50. de Mello Schier AR, de Oliveira Ribeiro NP, Coutinho DS, et al. Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa. CNS Neurol Disord Drug Targets 2014; 13(6):953-960.